|
Lilly/Incyte pill beats placebo in mid-stage eczema trial
WHTC The Phase 2 eczema trial found that after 16 weeks, 61 percent of patients on the highest dose of baricitinib and a topical corticosteroid had at least a 50 percent reduction in symptoms, compared to 37 percent of patients treated with just a steroid … |
Tag Archives: beats
Lilly/Incyte pill beats placebo in mid-stage eczema trial – WHTC
Reuters |
Lilly/Incyte pill beats placebo in mid-stage eczema trial
WHTC The Phase 2 eczema trial found that after 16 weeks, 61 percent of patients on the highest dose of baricitinib and a topical corticosteroid had at least a 50 percent reduction in symptoms, compared to 37 percent of patients treated with just a steroid … Baricitinib improves outcomes in patients with atopic dermatitis Lilly's baricitinib fails to outshine Sanofi's Dupixent Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |